
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Other Equity
OSE Immunotherapeutics SA
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Other Equity
-€1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
Other Equity
-€3.2m
|
CAGR 3-Years
-1 366%
|
CAGR 5-Years
-401%
|
CAGR 10-Years
N/A
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Equity
-€454k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Inventiva SA
PAR:IVA
|
Other Equity
-€1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
DBV Technologies SA
PAR:DBV
|
Other Equity
-$12.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Other Equity
-€1k
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Other Equity?
Other Equity
-1k
EUR
Based on the financial report for Dec 31, 2024, OSE Immunotherapeutics SA's Other Equity amounts to -1k EUR.